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clastogenesis via interaction with its receptor, RANK, whereas
OPG inhibits this osteoclastogenesis by acting as a soluble
RANKL receptor competitor. We previously reported that human
OA subchondral bone osteoblasts could be discriminated into
two subpopulations identiﬁed by their levels of endogenous pro-
duction (low [L] or high [H]) of PGE2. Firstly, we analysed and
compared the histology of human subchondral bone from nor-
mal, L and H OA. Then, we investigated on each of these human
subchondral bone osteoblast categories the OPG and RANKL
levels on these two factors, as well as the activity of each OA
osteoblast category on the osteoclast differentiation. Further, we
determined on L and H OA osteoblasts the modulation of some
bone remodelling factors on the RANKL level.
Methods: Histology of the human subchondral bone was per-
formed on knee specimens. Gene expression was determined
using real-time PCR, PGE2 and OPG protein production by spe-
ciﬁc ELISA, and membranous RANKL by ﬂow cytometry method-
ology. Osteoclast differentiation and formation was assayed by
using the pre-osteoclastic cell line RAW 264.7, which differenti-
ates only in the presence of RANKL. Modulation of membranous
RANKL on L and H OA osteoblasts was monitored following
treatment with osteotropic factors.
Results: Histology analysis revealed that the L OA osteoblasts
had a reduced subchondral bone mass compared to normal,
in contrast to the H OA which showed an increase. The
OPG/RANKL mRNA ratio was signiﬁcantly decreased in L OA
compared to normal or H OA, and markedly increased in H OA
compared to normal, suggesting an increased level of remod-
elling activity in L OA cells. This was further supported by the
membranous RANKL levels which were signiﬁcantly elevated in
L OA compared to the H OA and normal cells. Moreover, L OA,
but not H OA, cells induced a signiﬁcantly higher level of osteo-
clast differentiation and formation. Experiments with osteotropic
factors revealed that in L OA osteoblasts, TNF-α and Vitamin D3
signiﬁcantly increased the membranous RANKL level, a situation
not found for the H OA osteoblasts.
Conclusions: The differential abnormal levels of OPG and
RANKL, and consequently the OPG/RANKL ratio in the two
human OA subchondral bone osteoblast subpopulations, indi-
cate different stages of this diseased tissue, in which the L OA
osteoblasts favour bone resorption/remodelling activity. This ap-
pears to be related to an increased level of RANKL. A better
understanding of the modulation of subchondral bone RANKL
during the OA process should aid the development of a speciﬁc
therapeutic.
14
PROTEINASE-ACTIVATEDRECEPTOR (PAR)-2 IN
OSTEOARTHRITIC SUBCHONDRAL BONE
OSTEOBLASTS: IDENTIFICATION OF A NEW
THERAPEUTIC TARGET
N. Amiable1, S. Kwan Tat1, J. Martel-Pelletier1, F. Mineau1,
N. Duval2, J-P. Pelletier1, C. Boileau1
1Osteoarthritis Research Unit, University of Montreal Hospital
Centre, Notre-Dame Hospital, Montreal, PQ, Canada; 2Pavillon
des Charmilles, Vimont, PQ, Canada
Purpose: Proteinase-activated receptors (PARs) represent a
family of 7-transmembrane domain G protein coupled recep-
tors. PARs are activated by a unique mechanism of cleavage
generating a tethered activating ligand at the N-terminus. One
of the members of this family, PAR-2, has been shown to be in-
volved in inﬂammatory pathways. Our recent work demonstrated
that PAR-2 plays an important role in catabolic and proinﬂam-
matory pathways in cartilage degradation during osteoarthritis
(OA) in humans. Studies have also shown that subchondral
bone alteration/remodelling is intimately involved with cartilage
degeneration. Bone remodelling is closely regulated by a molec-
ular triad composed of OPG/RANK/RANKL, in which OPG and
RANKL are produced by osteoblasts. RANKL is known to be an
important factor in the induction of osteoclastogenesis, whereas
OPG inhibits this process.The aim of this study was to evaluate
the involvement of PAR-2 in human OA subchondral bone. To this
end, we investigated on human subchondral bone osteoblasts
the levels of PAR-2, OPG, and RANKL, comparing normal with
OA. The role of PAR-2 on the major bone remodelling factors,
OPG and RANKL, was also evaluated on OA subchondral bone
osteoblasts.
Methods: The in situ levels of PAR-2, OPG and RANKL ex-
pression were determined using real time RT-PCR. The level of
PAR-2 protein was analysed by Western blot, the membranous
RANKL by ﬂow cytometry and OPG by a speciﬁc ELISA.
Results: PAR-2 was expressed and produced in human nor-
mal subchondral bone osteoblasts, and a statistically signiﬁcant
(p<0.05) increase found in the OA cells. Both RANKL and OPG
expression were increased in OA subchondral bone osteoblasts,
as were the RANKL membranous protein levels and OPG pro-
duction (p<0.03, p<0.05, respectively). PAR-2 activation with a
speciﬁc agonist, SLIGKV-NH2 (PAR-2-AP; 400 µM), resulted in a
signiﬁcant increase (p<0.0001) in membranous RANKL on both
normal and OA osteoblasts, but had no effect on OPG produc-
tion, indicating that PAR-2 activation favours bone resorption.
Conclusions: This study demonstrates an increased level of
PAR-2 in human OA subchondral bone osteoblasts, and shows,
for the ﬁrst time, that speciﬁc PAR-2 activation upregulates a
major factor (RANKL) involved in the remodelling process of
this tissue. These results shed new light on the involvement of
PAR-2 in OA pathophysiology, suggesting PAR-2 as a potential
new therapeutic approach for the treatment of OA, not only for
cartilage but also at the subchondral bone level
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Purpose: Cartilage degeneration is the central feature in os-
teoarthritis (OA), but it is associated with concomitant changes in
all the structures of the joint, in particular the subchondral bone.
Articular chondrocytes express and synthesize OPG, RANK and
RANKL. However, in spite of the relevance of these proteins in
the adjacent bone metabolism, there is still little known about
their regulation in the cartilage. Our aim was to explore the role
of PGE2, the eicosanoid found at the higher concentration in OA
joints, in the expression and synthesis of OPG and RANKL in
human osteoarthritic chondrocytes (HOC) in culture.
Methods: HOC were obtained from the joint specimens of OA
patients who underwent total knee replacement surgery. The
gene expression of OPG and RANKL were assessed in HOC
stimulated with PGE2 by quantitative PCR, and the correspond-
ing protein synthesis was studied by western-blot. We also ex-
amined which of the four different PGE2 receptors (EP receptors)
was involved in the PGE2 action using speciﬁc EP agonists.
Results: PGE2 elicited a dose and time-dependent increase in
the gene expression and protein synthesis of OPG, with a peak
at 24 hours of incubation (gene expression: 2.8-fold increase;
protein: 3.5-fold increase, both for 10-6M PGE2 vs. unstimulated
HOC). Exposure to PGE2 also resulted in a dose and time-
dependent increase in the presence of RANKL, peaking at 24 h
of incubation (gene expression: 8-fold for 10-6M PGE2 vs. un-
